The 2026 "Diagnostic-Vaccine" Synergy
The diagnostic landscape is being reshaped by the impending 2026/2027 launch of the VLA15 (Pfizer/Valneva) vaccine.
The OspA Challenge: Because the vaccine targets the OspA protein, 2026 diagnostics must be able to differentiate between vaccine-induced antibodies and actual infection.
Differentiator Tests: Labs are rolling out specific panels that exclude OspA to ensure that vaccinated individuals can still be accurately diagnosed if they suffer a "breakthrough" infection.
1 View